Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer
Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center
Abstract
Twenty-three percent of patients missed taking tamoxifen on more than one fifth of days studied, although on average, patients filled prescriptions for tamoxifen for 87% of their first year of treatment. The youngest, oldest, nonwhite, and mastectomy patients had significantly lower rates of adherence; patients who had seen an oncologist before taking tamoxifen had significantly higher rates of adherence. Overall adherence decreased to 50% by year 4 of therapy.
The mean level of adherence to tamoxifen is high compared with other chronic medications. However, nearly one fourth of patients may be at risk for inadequate clinical response because of poor adherence. Because of the efficacy of tamoxifen therapy in preventing recurrence and death in women with early-stage breast cancer, further efforts are necessary to identify and prevent suboptimal adherence.
Citation impact
- FWCI
- 7.08
- Percentile
- 100%
- References
- 47
Authors
4- AHAnn H. PartridgeCorresponding
Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center
- PSPhilip S. Wang
Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center
- EPEric P. Winer
Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center
- JAJerry Avorn
Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center
Topics & keywords
- Tamoxifen
- Medicine
- Breast cancer
- Adjuvant therapy
- Mastectomy
- Internal medicine
- Oncology
- Population
- No poverty